- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/11 | 0.33 | 12.33 | -9.25 | 3.56 | -15.61 | 0.92 | N/A | - | ||
2024/10 | 0.29 | -2.72 | -35.21 | 3.23 | -16.21 | 0.92 | N/A | - | ||
2024/9 | 0.3 | -7.47 | -14.0 | 2.93 | -13.68 | 0.97 | 0.65 | - | ||
2024/8 | 0.33 | -6.25 | -9.22 | 2.63 | -13.64 | 0.92 | 0.68 | - | ||
2024/7 | 0.35 | 38.93 | -4.29 | 2.31 | -14.23 | 0.89 | 0.7 | - | ||
2024/6 | 0.25 | -15.99 | -38.61 | 1.96 | -15.78 | 0.83 | 0.85 | - | ||
2024/5 | 0.3 | 4.52 | -23.04 | 1.71 | -10.94 | 0.85 | 0.84 | - | ||
2024/4 | 0.28 | 7.22 | -8.9 | 1.41 | -7.89 | 0.86 | 0.82 | - | ||
2024/3 | 0.27 | -15.07 | -32.5 | 1.13 | -7.63 | 1.13 | 0.63 | - | ||
2024/2 | 0.31 | -43.17 | -8.26 | 0.86 | 4.17 | 1.23 | 0.58 | - | ||
2024/1 | 0.55 | 50.06 | 12.87 | 0.55 | 12.87 | 1.28 | 0.55 | - | ||
2023/12 | 0.37 | 1.08 | -13.2 | 4.58 | -13.94 | 1.18 | 0.64 | - | ||
2023/11 | 0.36 | -19.79 | -30.72 | 4.21 | -14.01 | 1.17 | 0.65 | - | ||
2023/10 | 0.45 | 29.11 | 8.04 | 3.85 | -12.01 | 1.16 | 0.65 | - | ||
2023/9 | 0.35 | -2.33 | -4.66 | 3.4 | -14.13 | 1.07 | 0.79 | - | ||
2023/8 | 0.36 | -1.16 | -23.24 | 3.05 | -15.1 | 1.13 | 0.75 | - | ||
2023/7 | 0.36 | -10.89 | -4.02 | 2.69 | -13.88 | 1.16 | 0.73 | - | ||
2023/6 | 0.41 | 5.31 | 0.41 | 2.33 | -15.24 | 1.11 | 0.87 | - | ||
2023/5 | 0.39 | 23.73 | -0.62 | 1.92 | -17.95 | 1.09 | 0.88 | - | ||
2023/4 | 0.31 | -20.55 | -28.37 | 1.53 | -21.41 | 1.05 | 0.92 | - | ||
2023/3 | 0.39 | 15.42 | -15.84 | 1.22 | -19.4 | 1.22 | 0.84 | - | ||
2023/2 | 0.34 | -30.08 | -24.47 | 0.83 | -20.99 | 1.25 | 0.82 | - | ||
2023/1 | 0.49 | 15.39 | -18.36 | 0.49 | -18.36 | 1.43 | 0.72 | - | ||
2022/12 | 0.42 | -19.32 | -8.37 | 5.32 | -6.56 | 1.36 | 0.7 | - | ||
2022/11 | 0.52 | 25.09 | -8.19 | 4.9 | -6.4 | 1.31 | 0.73 | - | ||
2022/10 | 0.42 | 13.92 | -29.48 | 4.38 | -6.18 | 1.25 | 0.76 | - | ||
2022/9 | 0.37 | -21.36 | -29.31 | 3.96 | -2.78 | 1.21 | 0.8 | - | ||
2022/8 | 0.47 | 23.58 | -17.14 | 3.59 | 1.09 | 1.25 | 0.78 | - | ||
2022/7 | 0.38 | -6.77 | -23.2 | 3.12 | 4.53 | 1.17 | 0.83 | - | ||
2022/6 | 0.41 | 4.23 | -33.33 | 2.75 | 10.0 | 1.23 | 0.69 | - | ||
2022/5 | 0.39 | -10.82 | 3.69 | 2.34 | 23.96 | 1.29 | 0.66 | - | ||
2022/4 | 0.44 | -6.66 | 10.62 | 1.95 | 28.99 | 1.36 | 0.63 | - | ||
2022/3 | 0.47 | 3.58 | 5.86 | 1.52 | 35.47 | 1.52 | 0.44 | - | ||
2022/2 | 0.45 | -24.42 | 81.04 | 1.05 | 54.77 | 1.51 | 0.44 | 本公司提升免疫力產品,受疫情影響銷量增加,及代理巿場熱門石墨烯商品,導致營收增加。 | ||
2022/1 | 0.6 | 29.5 | 39.47 | 0.6 | 39.47 | 1.63 | 0.41 | - | ||
2021/12 | 0.46 | -19.16 | 4.28 | 5.7 | 32.89 | 1.62 | 0.38 | - | ||
2021/11 | 0.57 | -3.9 | 59.44 | 5.24 | 36.18 | 1.68 | 0.36 | 防疫期間新品上市與提升免疫產品銷量增加,導致營收較去年同期增加 | ||
2021/10 | 0.59 | 14.18 | 86.36 | 4.67 | 33.79 | 1.68 | 0.36 | 防疫期間新品上市與提升免疫產品銷量增加,導致營收較去年同期增加 | ||
2021/9 | 0.52 | -7.82 | 73.31 | 4.07 | 28.51 | 1.58 | 0.41 | 防疫期間消費者透過電視、網路購物比重提高,及新品上市與提升免疫產品銷量增加,導致營收較去年同期增加 | ||
2021/8 | 0.56 | 14.55 | 84.73 | 3.55 | 23.82 | 1.66 | 0.38 | 防疫期間消費者透過電視、網路購物比重提高,及新品上市,導致營收較去年同期增加 | ||
2021/7 | 0.49 | -19.07 | 54.59 | 2.99 | 16.57 | 1.48 | 0.43 | 受疫情影響,提升免疫產品銷量大幅增加。 | ||
2021/6 | 0.61 | 62.11 | 92.64 | 2.5 | 11.18 | 1.38 | 0.45 | 受疫情影響,防疫產品銷量大幅增加。 | ||
2021/5 | 0.38 | -4.85 | -1.63 | 1.89 | -2.14 | 1.21 | 0.51 | - | ||
2021/4 | 0.39 | -10.68 | 10.09 | 1.51 | -2.26 | 1.09 | 0.57 | - | ||
2021/3 | 0.44 | 77.15 | 21.23 | 1.12 | -5.98 | 1.12 | 0.46 | - | ||
2021/2 | 0.25 | -41.77 | -38.71 | 0.68 | -17.99 | 1.12 | 0.46 | - | ||
2021/1 | 0.43 | -3.17 | 2.11 | 0.43 | 2.11 | 1.23 | 0.42 | - | ||
2020/12 | 0.44 | 23.59 | -15.42 | 4.29 | -1.35 | 1.12 | 0.47 | - | ||
2020/11 | 0.36 | 12.31 | -15.3 | 3.85 | 0.56 | 0.98 | 0.54 | - | ||
2020/10 | 0.32 | 6.19 | -20.19 | 3.49 | 2.53 | 0.92 | 0.57 | - | ||
2020/9 | 0.3 | -1.75 | 2.99 | 3.17 | 5.55 | 0.92 | 0.58 | - | ||
2020/8 | 0.31 | -4.13 | 22.17 | 2.87 | 5.83 | 0.94 | 0.57 | - | ||
2020/7 | 0.32 | 0.84 | -15.81 | 2.56 | 4.17 | 1.02 | 0.53 | - | ||
2020/6 | 0.32 | -17.22 | 4.15 | 2.25 | 7.79 | 1.06 | 0.51 | - | ||
2020/5 | 0.38 | 6.48 | -2.3 | 1.93 | 8.42 | 1.1 | 0.49 | - | ||
2020/4 | 0.36 | -1.64 | 13.89 | 1.55 | 11.43 | 1.13 | 0.48 | - | ||
2020/3 | 0.36 | -10.44 | 16.75 | 1.19 | 10.71 | 1.19 | 0.53 | - | ||
2020/2 | 0.41 | -2.98 | 49.68 | 0.83 | 8.24 | 1.35 | 0.47 | - | ||
2020/1 | 0.42 | -19.8 | -14.67 | 0.42 | -14.67 | 0.0 | N/A | - | ||
2019/12 | 0.52 | 23.76 | 50.18 | 4.35 | -18.44 | 0.0 | N/A | 新品上市,致本月銷售金額增加。 |
年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
---|---|---|---|---|---|---|---|---|---|
2024/1 | 0.55 | 2023/1 | 0.49 | 2022/1 | 0.6 | 2021/1 | 0.43 | 2020/1 | 0.42 |
2024/2 | 0.31 | 2023/2 | 0.34 | 2022/2 | 0.45 | 2021/2 | 0.25 | 2020/2 | 0.41 |
2024/3 | 0.27 | 2023/3 | 0.39 | 2022/3 | 0.47 | 2021/3 | 0.44 | 2020/3 | 0.36 |
2024/4 | 0.28 | 2023/4 | 0.31 | 2022/4 | 0.44 | 2021/4 | 0.39 | 2020/4 | 0.36 |
2024/5 | 0.3 | 2023/5 | 0.39 | 2022/5 | 0.39 | 2021/5 | 0.38 | 2020/5 | 0.38 |
2024/6 | 0.25 | 2023/6 | 0.41 | 2022/6 | 0.41 | 2021/6 | 0.61 | 2020/6 | 0.32 |
2024/7 | 0.35 | 2023/7 | 0.36 | 2022/7 | 0.38 | 2021/7 | 0.49 | 2020/7 | 0.32 |
2024/8 | 0.33 | 2023/8 | 0.36 | 2022/8 | 0.47 | 2021/8 | 0.56 | 2020/8 | 0.31 |
2024/9 | 0.3 | 2023/9 | 0.35 | 2022/9 | 0.37 | 2021/9 | 0.52 | 2020/9 | 0.3 |
2024/10 | 0.29 | 2023/10 | 0.45 | 2022/10 | 0.42 | 2021/10 | 0.59 | 2020/10 | 0.32 |
2024/11 | 0.33 | 2023/11 | 0.36 | 2022/11 | 0.52 | 2021/11 | 0.57 | 2020/11 | 0.36 |
N/A | N/A | 2023/12 | 0.37 | 2022/12 | 0.42 | 2021/12 | 0.46 | 2020/12 | 0.44 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
合約負債 QoQ YoY |
---|